• Q3 consolidated net profit was up 2.82% YoY at Rs 3,052.9 cr. • Consolidated revenue from operations was up 14.35% YoY at Rs 23,229 cr. • It announced an interim dividend of Rs 1/share and the record date is January 25, 2023.
• Q3 revenue up 17.1% YoY at Rs 3,203.14 cr • Net loss was at Rs 1,594 cr vs profit of Rs 240.8 cr YoY
Dr. Reddy's acquired the trademark rights for the breast cancer drug PRIMCYV from Pfizer Products India for use in the Indian market.
Check More Details